Suzhou Zelgen Biopharmaceuticals Co Ltd Asset Resilience Ratio

Latest as of September 2025: 0.54%

Suzhou Zelgen Biopharmaceuticals Co Ltd asset resilience ratio. Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has an Asset Resilience Ratio of 0.54% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Suzhou Zelgen Biopharmaceuticals Co Ltd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥16.20 Million
≈ $2.37 Million USD Cash + Short-term Investments

Total Assets

CN¥3.01 Billion
≈ $440.95 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Suzhou Zelgen Biopharmaceuticals Co Ltd (2019–2024)

Asset resilience ratio of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2019 to 2024. This chart shows how Suzhou Zelgen Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Read 688266 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Suzhou Zelgen Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 688266 total asset value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥16.20 Million 0.54%
Total Liquid Assets CN¥16.20 Million 0.54%

Asset Resilience Insights

  • Limited Liquidity: Suzhou Zelgen Biopharmaceuticals Co Ltd maintains only 0.54% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Suzhou Zelgen Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio

Compare Suzhou Zelgen Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 36.07%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
3SBio Inc
F:83B
Biotechnology 10.64%

Suzhou Zelgen Biopharmaceuticals Co Ltd Asset Resilience Ratio by Year (2019–2024)

Suzhou Zelgen Biopharmaceuticals Co Ltd asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.35% CN¥40.50 Million
≈ $5.93 Million
CN¥3.00 Billion
≈ $439.67 Million
-3.40pp
2023-12-31 4.75% CN¥137.02 Million
≈ $20.05 Million
CN¥2.89 Billion
≈ $422.49 Million
-10.18pp
2022-12-31 14.92% CN¥248.93 Million
≈ $36.43 Million
CN¥1.67 Billion
≈ $244.13 Million
+11.18pp
2021-12-31 3.74% CN¥65.26 Million
≈ $9.55 Million
CN¥1.75 Billion
≈ $255.49 Million
-19.09pp
2020-12-31 22.83% CN¥449.85 Million
≈ $65.83 Million
CN¥1.97 Billion
≈ $288.31 Million
+20.96pp
2019-12-31 1.87% CN¥6.00 Million
≈ $877.99K
CN¥320.27 Million
≈ $46.87 Million
--
pp = percentage points

About Suzhou Zelgen Biopharmaceuticals Co Ltd

SHG:688266 China Biotechnology
Market Cap
$3.52 Billion
CN¥24.04 Billion CNY
Market Cap Rank
#4315 Global
#628 in China
Share Price
CN¥90.80
Change (1 day)
-0.49%
52-Week Range
CN¥75.75 - CN¥147.40
All Time High
CN¥147.40
About

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate … Read more